GLP-1 Receptor Agonist Market is Growing at a CAGR of 13.3% from 2023-2030, Top Companies Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, AstraZeneca

According to the new market research report "GLP-1 Receptor Agonist Market, By Drug Type (Exenatide, Liraglutide, Dulaglutide, Semaglutide, and others), Brand (Bydureon, Victoza, Trulicity, Ozempic, and Others), Route of Administration (Injectable, Oral Formulations), Application (Type 2 Diabetes, Obesity, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)", published by Delvens, the global GLP-1 Receptor Agonist Market size is projected to reach a CAGR of 13.3% from 2023-2030.

This wide-ranging and elaborate primary analysis report highlights numerous facts such as development factors, business enhancement strategies, statistical growth, financial gain or loss to help readers and clients to understand the market on a global scale. To generate this world-class GLP-1 Receptor Agonist Market report, the combination of best industry insight, practical solutions, talent solutions and latest technology have been used. The GLP-1 Receptor Agonist Market report is formulated based on the market type, organization size, availability on-premises, the end-users' organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Request For Free Sample Report: https://www.delvens.com/get-free-sample/glp1-receptor-agonist-market-trends-forecast-till-2030

Top Players covered in GLP-1 Receptor Agonist Market report:

Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma, Inc.

In May 2022, The US Food and Drug Administration (FDA granted approval for Eli Lilly and Company's Mounjaro (tripeptide) injection as an adjunct to diet and exercise to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

In July 2021, AstraZeneca's Bydureon BCise (exenatide extended-release), the once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years).

Glucagon-like peptide-1 (GLP-1) receptor agonists bind to GLP-1 receptors and activate them to stimulate physiological processes in the body. GLP-1 receptor agonists interact with GLP-1 receptors present in the pancreatic beta cells to stimulate insulin secretion. Thus, GLP-1 receptor agonists can be used for the treatment of diabetes. The benefits of using GLP-1 receptor agonists for the treatment of type-2 diabetes include inhibition of glucagon production from pancreatic alpha cells in case of high blood sugar levels. Glucagon is a hormone responsible for increasing the concentration of glucose in the blood by stimulating the liver to convert glycogen into glucose. Moreover, GLP-1 receptor agonists can promote the proliferation of pancreatic beta-cell and decrease their apoptosis or cell death. Also, GLP-1 receptor agonists slow down the emptying of gastric juices which leads to the slow release of nutrients from the food, thus it prevents the spiking of blood glucose levels. GLP-1 receptor agonists can also be used to treat several other conditions such as obesity, liver cirrhosis, cardiovascular disease, and others.

Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are the overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time, rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes and growing number of middle-class households, rise in the per capita income and increasing expenditure are one of the main contributors of the market growth. In addition, the enhanced healthcare infrastructure, technological developments, and the accessibility of skilled medical professionals will further provide potential opportunities for the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the coming years.

On the other hand, the two major factors restraining the growth of the market are adverse effects related to the use of GLP-1 receptor agonist drugs and product recalls by market players.

COVID-19 has positively affected the glucagon-like peptide 1 (GLP-1) agonists market. During the lockdowns and isolation during the pandemic complicated diabetes management and medication adherence. Glucagon-like peptide 1 (GLP-1) agonists market promises due to their anti-inflammatory and anti-obesogenic qualities, as well as pulmonary protection and a positive impact on gut microbiota composition. Taking everything into account, the glucagon-like peptide 1 (GLP-1) agonists market appears to be a promising option for the treatment of COVID-19-infected patients with or without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) medications during COVID-19 pandemics.

Make an Inquiry: https://www.delvens.com/Inquire-before-buying/glp1-receptor-agonist-market-trends-forecast-till-2030

GLP-1 Receptor Agonist Market: Key Findings

The Drug type Segment is further fragmented into Exenatide, Liraglutide, Dulaglutide, Semaglutide, and others. Semaglutide is expected to be the fastest-growing segment in the GLP-1 receptor agonist market, driven by its efficacy and once-weekly dosing regimen. Exenatide and liraglutide are also expected to grow steadily, while dulaglutide and others may face some competition from new entrants.

The Brand Segment is further fragmented into Bydureon, Victoza, Trulicity, Ozempic, and Others. Novo Nordisk's semaglutide is expected to be the fastest-growing brand in the GLP-1 receptor agonist market, as it has shown superior efficacy compared to other drugs in the class. Eli Lilly's tripeptide and Chiasma's oral octreotide also have the potential to disrupt the market, though they are still in clinical trials.

The Route of Administration Segments is further fragmented into Injectable, Oral Formulations. The oral GLP-1 receptor agonist segment is expected to be the fastest-growing, as it offers greater convenience and ease of use for patients. However, injectable formulations will continue to dominate the market, especially for patients with more severe cases of diabetes and obesity.

The Application Segment is further fragmented into Type 2 Diabetes, Obesity, and Others. The type 2 diabetes segment is expected to account for the largest share of the GLP-1 receptor agonist market, as diabetes is a major and growing public health concern worldwide. However, the obesity segment is also expected to grow rapidly, as GLP-1 receptor agonists have shown promise in promoting weight loss and improving metabolic health.

The Region Segment is further fragmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. North America is expected to be the largest and fastest-growing market for GLP-1 receptor agonists, driven by high awareness of diabetes and obesity, strong healthcare infrastructure, and favourable reimbursement policies. Asia-Pacific is also expected to grow rapidly, as rising disposable incomes and increasing urbanization contribute to higher rates of diabetes and obesity.

North America to Dominate the Market

North America dominates the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in healthcare.

Furthermore, the growing research and development. Furthermore, the occurrence of major key players will further boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region during the forecast period.

Delvens Industry Expert's Standpoint

Within the pharmaceutical sector, the GLP-1 receptor agonist market is a fast-expanding and changing subsegment. This market is expanding as a result of rising rates of diabetes and obesity, improvements in medication research, and greater public awareness of the value of disease management. The market is now controlled by a small number of significant competitors, including Novo Nordisk and Eli Lilly, although there is room for disruption from more recent entries with novel oral formulations and drug delivery systems. The oral GLP-1 receptor agonist market is anticipated to develop at the quickest rate in the upcoming years as the market expands. The category for type 2 diabetes is anticipated to have the biggest market share, while the segment for obesity is anticipated to expand quickly as well. The largest and fastest-growing markets are predicted to be in North America and Asia-Pacific. Overall, the market for GLP-1 receptor agonists offers tremendous opportunities for pharmaceutical firms to create and distribute ground-breaking treatments for diabetes and obesity that will enhance the lives of millions of people worldwide.

GLP-1 Receptor Agonist Market: Table of Contents

GLP-1 Receptor Agonist Market is segmented into various segments such as drugs type, brand, route of administration, application, and region:

On the basis of drug type

Exenatide
Liraglutide
Dulaglutide
Semaglutide

On the basis of brand

Bydureon
Victoza
Trulicity
Ozempic
Others

On the basis of the route of administration

Injectable
Oral Formulations

On the basis of the application

Type 2 diabetes
Obesity
Others

On the basis of region

Asia Pacific
North America
Europe
South America
Middle East & Africa

The prominent players in GLP-1 Receptor Agonist Market are

Eli Lilly and Company
GlaxoSmithKline plc
Novo Nordisk A/S
PegBio Co., Ltd.
AstraZeneca
Intarcia Therapeutics, Inc.
Amylin Pharmaceuticals, Inc.
Sanofi
Hanmi Pharm. Co., Ltd.
Pfizer Inc.
Amgen Inc.
Innovent Biologics
Jiangsu Hengrui Medicine Co.
Sun Pharmaceuticals Industries Ltd.
9 Meters Biopharma, Inc.

Buy Now: https://www.delvens.com/checkout/glp1-receptor-agonist-market-trends-forecast-till-2030

Contact Us:

UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
SALES@DELVENS.COM
WEBSITE: https://delvens.com/

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

This release was published on openPR.